Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02807454
Title A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

multiple myeloma

Therapies

Daratumumab + Dexamethasone + Durvalumab + Pomalidomide

Daratumumab + Durvalumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN | BEL


No variant requirements are available.